Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

721. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials

The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials The role of angiotensin receptor blockers (...) and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials Madrid A H, Peng J, Zamora J, Marin I, Bernal E, Escobar C, Munos-Tinoco C, Rebollo J M, Moro C CRD summary This review assessed the effects of angiotensin II type-1 receptor blockers and/or angiotensin-converting enzyme inhibitors in the prevention of atrial fibrillation. The authors concluded that treatment with these drugs

DARE.2004

722. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease

Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease Shekelle P G, Morton S C, Jungvig L K, Udani J, Spar M, Tu W, Suttorp M J, Coulter I, Newberry S J, Hardy M CRD summary This review assessed the effectiveness of vitamin E supplementation for the prevention and treatment (...) of cardiovascular disease. The authors concluded that there is good evidence that vitamin E supplementation does not beneficially or adversely affect cardiovascular outcomes. This was a very well-conducted systematic review and the authors' conclusions are likely to be reliable. Authors' objectives To assess the effectiveness of vitamin E supplementation for the prevention and treatment of cardiovascular disease. Searching MEDLINE, EMBASE, MANTIS, AMED, BIOSIS Previews, CAB Health, Cancerlit, Social SciSearch

DARE.2004

723. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease

Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease Balk E, Chung M, Lichtenstein A, Chew P, Kupelnick B, Lawrence A, DeVine D, Lau J Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Balk E, Chung M, Lichtenstein A, Chew P, Kupelnick B, Lawrence A, DeVine D, Lau J. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 93. 2004 Authors' objectives As the second of a 3-part report on this topic, we

Health Technology Assessment (HTA) Database.2004

724. Effects of omega-3 fatty acids on cardiovascular disease

Effects of omega-3 fatty acids on cardiovascular disease Effects of omega-3 fatty acids on cardiovascular disease Effects of omega-3 fatty acids on cardiovascular disease Wang C, Chung M, Lichtenstein A, Balk E, Kupelnick B, DeVine D, Lawrence A, Lau J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wang C, Chung M, Lichtenstein A, Balk E (...) , Kupelnick B, DeVine D, Lawrence A, Lau J. Effects of omega-3 fatty acids on cardiovascular disease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 94. 2004 Authors' objectives As the first of a 3-part report on this topic, we analyzed relevant nutrition databases to describe the intake levels of various omega-3 fatty acids in the US population. We also performed a systematic review of the literature to assess the benefits of omega-3 fatty acid

Health Technology Assessment (HTA) Database.2004

725. Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease

Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease: Recommendation statement from the Canadian Task Force on Preventive Health Care Information for… Search for Keyword: Submit Recommendations The Canadian Task Force on Preventive Health Care concludes that there is fair evidence to recommend against the use of hormone (...) replacement therapy (HRT) for the primary prevention of myocardial infarction and death from cardiovascular disease in perimenopausal women without established coronary artery disease (CAD) (grade D recommendation). There is insufficient evidence to make a recommendation on the use of HRT for the primary prevention of stroke and death from cerebrovascular disease. However, because stroke is a major cause of morbidity and death among Canadian women, other beneficial preventive measures, such as aggressive treatment

CMA Infobase (Canada)2004 Full Text: Link to full Text with Trip Pro

726. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. 15536108 2004 11 10 2004 11 15 2016 11 24 1538-3598 292 18 2004 Nov 10 JAMA JAMA Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. 2217-25 The effect of antihypertensive drugs on cardiovascular events (...) in patients with coronary artery disease (CAD) and normal blood pressure remains uncertain. To compare the effects of amlodipine or enalapril vs placebo on cardiovascular events in patients with CAD. Double-blind, randomized, multicenter, 24-month trial (enrollment April 1999-April 2002) comparing amlodipine or enalapril with placebo in 1991 patients with angiographically documented CAD (>20% stenosis by coronary angiography) and diastolic blood pressure <100 mm Hg. A substudy of 274 patients measured

JAMA2004

727. Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors.

Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors. CONTEXT: Low cardiorespiratory fitness is an established risk factor for cardiovascular and total mortality; however, mechanisms responsible for these associations are uncertain. OBJECTIVE: To test whether low fitness, estimated by short duration on a maximal treadmill test, predicted the development of cardiovascular disease risk factors and whether improving fitness (increase in treadmill (...) with the development of cardiovascular disease risk factors. These associations involve obesity and may be modified by improving fitness.

JAMA2003

728. Association between estrogen receptor alpha gene variation and cardiovascular disease.

Association between estrogen receptor alpha gene variation and cardiovascular disease. CONTEXT: Estrogen and related hormone therapies activate estrogen receptors, which in turn regulate genes for several cardiovascular disease (CVD) risk factors. Relatively little is known, however, about the impact of genetic variation in estrogen receptor alpha (ESR1) on CVD risk. OBJECTIVE: To investigate whether the ESR1 c.454-397T>C polymorphism is associated with CVD risk. DESIGN, SETTING (...) , AND PARTICIPANTS: Prospective study of 1739 unrelated men and women from the population-based offspring cohort of the Framingham Heart Study, who were followed up from 1971 to 1998. MAIN OUTCOME MEASURES: Total atherosclerotic CVD events, defined as recognized or unrecognized myocardial infarction (MI), angina pectoris, coronary insufficiency, intermittent claudication, coronary heart disease death, or atherothrombotic stroke (n = 178); major atherosclerotic CVD, defined as recognized acute MI, coronary

JAMA2003

729. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease.

Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. BACKGROUND: Cellular antioxidant enzymes such as glutathione peroxidase 1 and superoxide dismutase have a central role in the control of reactive oxygen species. In vitro data and studies in animal models suggest that these enzymes may protect against atherosclerosis, but little is known about their relevance to human disease. METHODS: We conducted a prospective study among 636 patients (...) with suspected coronary artery disease, with a median follow-up period of 4.7 years (maximum, 5.4) to assess the risk of cardiovascular events associated with base-line erythrocyte glutathione peroxidase 1 and superoxide dismutase activity. RESULTS: Glutathione peroxidase 1 activity was among the strongest univariate predictors of the risk of cardiovascular events, whereas superoxide dismutase activity had no association with risk. The risk of cardiovascular events was inversely associated with increasing

NEJM2003

730. B-type natriuretic peptide in cardiovascular disease.

B-type natriuretic peptide in cardiovascular disease. Natriuretic peptide hormones, a family of vasoactive peptides with many favourable physiological properties, have emerged as important candidates for development of diagnostic tools and therapeutic agents in cardiovascular disease. The rapid incorporation into clinical practice of bioassays to measure natriuretic peptide concentrations, and drugs that augment the biological actions of this system, show the potential for translational

Lancet2003

731. Routine vitamin supplementation to prevent cancer and cardiovascular disease: recommendations and rationale.

Routine vitamin supplementation to prevent cancer and cardiovascular disease: recommendations and rationale. This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on routine vitamin supplementation to prevent cancer and cardiovascular disease and the supporting scientific evidence. Part of the information on which this statement is based, including evidence tables and references, is available in the accompanying article on vitamins to prevent cardiovascular (...) disease in this issue. More complete information can be found in the summaries of the evidence on vitamins to prevent cancer and vitamins to prevent cardiovascular disease, available on the USPSTF Web site (http://www.preventiveservices.ahrq.gov) and through the National Guideline Clearinghouse (http://www.guideline.gov). The summaries of the evidence on these topics and the recommendation statement are also available in print through subscription to the Guide to Clinical Preventive Services, Third

Annals of Internal Medicine2003

732. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force.

Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force. BACKGROUND: Antioxidant vitamins are thought to play a role in atherosclerosis. Supplementation of these nutrients has been explored as a means of reducing cardiovascular morbidity and mortality. PURPOSE: To assess the evidence of the effectiveness of vitamin supplementation, specifically vitamins A, C, and E; beta-carotene; folic acid; antioxidant (...) combinations; and multivitamin supplements, in preventing cardiovascular disease. DATA SOURCES: Cochrane Controlled Trials Registry and MEDLINE (1966 to September 2001), reference lists, and experts. STUDY SELECTION: The researchers selected English-language reports of randomized trials and cohort studies that assessed vitamin supplementation in western populations and reported incidence of or death from cardiovascular events. They also included reports of good- or fair-quality clinical trials of primary

Annals of Internal Medicine2003

733. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States.

Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. BACKGROUND: Few studies have examined the relationship between cigarette smoking and novel risk factors for cardiovascular disease in a general population or have included a biochemical marker of current smoking. OBJECTIVE: To examine the relationship between cigarette smoking and serum C-reactive protein, fibrinogen, and homocysteine levels. DESIGN: Cross-sectional study. SETTING (...) mmol/L, respectively). RESULTS: After adjustment for traditional cardiovascular disease risk factors, cigarette smoking was related to elevated levels of C-reactive protein, fibrinogen, and homocysteine. Compared with never smoking cigarettes, self-reported current cigarette smoking was associated with a C-reactive protein level in the detectable (odds ratio, 1.66 [95% CI, 1.40 to 1.97]; P < 0.001) or clinically elevated (odds ratio, 1.98 [CI, 1.57 to 2.51]; P < 0.001) ranges, with elevated

Annals of Internal Medicine2003

734. Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease.

Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease. Kawasaki disease is an acute vasculitis of possible infectious cause, which in particular affects the coronary arteries. Young children rely mostly on their innate immune system for protection against invading microorganisms, of which mannose-binding lectin is an important component. We aimed to investigate the possible role of the gene for this molecule (MBL) in white Dutch patients (...) with Kawasaki disease. In 90 patients, frequency of mutations in the MBL gene was higher than in healthy children. In children younger than 1 year, those with mutations were at higher risk of development of coronary artery lesions than were those without (odds ratio 15.7, 95% CI 1.4-176.5, p=0.026). Our findings suggest that the innate immune system contributes differently to pathophysiology of Kawasaki disease at various ages.

Lancet2003

735. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.

Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. CONTEXT: Formation of nitric oxide-derived oxidants may serve as a mechanism linking inflammation to development of atherosclerosis. Nitrotyrosine, a specific marker for protein modification by nitric oxide-derived oxidants, is enriched in human atherosclerotic lesions and low-density lipoprotein (LDL) recovered from human atheroma. OBJECTIVES: To determine whether systemic levels of nitrotyrosine (...) are associated with the prevalence of coronary artery disease (CAD) and are modulated by hydroxymethylglutaryl coenzyme-A reductase inhibitor (statin) therapy. DESIGN, SETTING, AND PATIENTS: A case-control and interventional study at 2 urban tertiary-care referral centers; recruitment for each was from June 1, 2001, until January 1, 2002. For the case-control study, 100 case-patients with established CAD and 108 patients with no clinically evident CAD were recruited consecutively. In the interventional study

JAMA2003

736. Cereal, fruit, and vegetable fiber intake and the risk of cardiovascular disease in elderly individuals.

Cereal, fruit, and vegetable fiber intake and the risk of cardiovascular disease in elderly individuals. CONTEXT: People older than 65 years are the fastest-growing segment of the population and account for the majority of cardiovascular disease (CVD) morbidity, mortality, and health care expenditures. Additionally, the influence of dietary habits on risk may be less pronounced in elderly persons, when atherosclerosis is more advanced. However, few data address the influence of diet on CVD risk (...) ) using a 99-item food frequency questionnaire. MAIN OUTCOME MEASURE: Incident CVD (combined stroke, ischemic heart disease death, and nonfatal myocardial infarction). RESULTS: During 8.6 years mean follow-up, there were 811 incident CVD events. After adjustment for age, sex, education, diabetes, ever smoking, pack-years of smoking, daily physical activity, exercise intensity, alcohol intake, and fruit and vegetable fiber consumption, cereal fiber consumption was inversely associated with incident CVD

JAMA2003

737. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk.

Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. BACKGROUND: Cardiovascular disease accounts for much morbidity and mortality in developed countries and is becoming increasingly important in less developed regions. Systolic blood pressure above 115 mm Hg accounts for two-thirds of strokes and almost half of ischaemic heart disease cases, and cholesterol concentrations exceeding (...) from estimates of burden of disease were used in a four-state longitudinal population model to calculate disability-adjusted life years (DALYs) averted and patients treated. Costs were taken from previous publications, or estimated by local experts, in 14 regions. FINDINGS: Non-personal health interventions, including government action to stimulate a reduction in the salt content of processed foods, are cost-effective ways to limit cardiovascular disease and could avert over 21 million DALYs per

Lancet2003

738. Folate and vitamin B-12 and risk of fatal cardiovascular disease: cohort study from Busselton, Western Australia.

Folate and vitamin B-12 and risk of fatal cardiovascular disease: cohort study from Busselton, Western Australia. OBJECTIVE: To test the hypothesis that the incidence of fatal coronary heart disease and cardiovascular disease in a general population is related to serum and red cell folate and vitamin B-12 concentrations. DESIGN: Cohort study with follow up of 29 years. SETTING: Busselton, Western Australia. PARTICIPANTS: 1419 men and 1531 women aged 20 to 90 years, who were alive more than (...) three years after their participation in the 1969 Busselton health survey. 2314 (78.4%) had no cardiovascular disease at the initial survey. MAIN OUTCOME MEASURES: Hazard ratios for fatal coronary heart disease and cardiovascular disease in men and women according to baseline concentrations of serum and red cell folate and serum vitamin B-12. RESULTS: 213 men and 159 women died from coronary heart disease, and 342 men and 302 women died from cardiovascular disease. Serum and red cell folate

BMJ2003 Full Text: Link to full Text with Trip Pro

739. Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations

Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations Abramson B L, with The Canadian (...) Task Force on Preventive Health Care Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Abramson B L, with The Canadian Task Force on Preventive Health Care. Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations. London, Ontario: Canadian Task Force on Preventive Health

Health Technology Assessment (HTA) Database.2003

740. Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease

Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease Shekelle P, Morton S, Hardy M Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shekelle P, Morton S, Hardy M. Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 83. 2003 Authors' objectives The purpose of this study was to conduct a systematic review

Health Technology Assessment (HTA) Database.2003